This action might not be possible to undo. Are you sure you want to continue?
of vertigo, tinnitus and sensorineural deafness) and vertigo of peripheral origin. Drug Classification: Anti emetics and Anti vertigo Mechanism of Action: Betahistine was found to have a histamine-like action in animals. Since parenteral histamine has been used in the treatment of Meniere's disease, studies were conducted to test the action of betahistine in this condition. Unlike some other anti-vertigo drugs, testing with nystagmus induced by caloric and rotational stimulation has demonstrated that betahistine does not decrease the vestibular response, as recorded by electronystagmography. In addition, the absorption, metabolism and action of betahistine when administered by the oral route are not known. However, clinical studies indicate that SERC may be useful in reducing the vertigo of Meniere's disease. Dosage: Adults: 24-48 mg divided over the day 8 mg tablets- 1-2 tablets, 3 times/day 16 mg tablets: 1 tablet, 3 times/day
Special Precaution: Patients suffering from pheochromocytoma, bronchial asthma need to be carefully monitored during the therapy. Caution should be taken in the treatment of patients with a history of peptic ulcer. Pregnancy risk category Adverse Effects: Occasionaly patients have experienced gastric upset, nausea and headache. Contraindication: Hypersensitivity to any component of the product. Form: Tablet 8 mg x 100’s, 16 mg x 100’s Nursing Responsibilities: Avoid contact of oral solution or injection with skin Raise bed rails, institute safety measures, supervise ambulation